Mira Halvorsen Børstad Appointed Chief Commercial Officer at Genetic Analysis
Genetic Analysis AS has appointed Mira Halvorsen Børstad as its Chief Commercial Officer. The appointment is expected to strengthen the company's commercial leadership as its GA-map® platform sees expanding adoption.
Genetic Analysis AS (GA) announced the appointment of Mira Halvorsen Børstad as Chief Commercial Officer (CCO). Børstad joined the company on September 1, 2026, and will lead GA’s commercial organization as part of the executive management team, reporting to CEO Ronny Hermansen.
The appointment follows continued commercial and scientific success for GA's GA-map® platform, with adoption expanding across the USA, Europe, Asia, and Australia. Børstad is expected to enhance the company's commercial leadership in the post-pandemic business environment.
GA specializes in microbiome diagnostics and develops the GA-map® platform. This platform facilitates the analysis of gut microbiome composition and has gained significant recognition globally.
The company anticipates that Børstad's experience in developing commercial strategies and driving growth will support GA's ongoing expansion into new markets and solidify its position in the microbiome diagnostics sector.